ALAXIN-SUSPENSION 160MG/80ML ORAL SUSPENSION

Indications

• Uncomplicated malaria caused by Plasmodium falciparum
• Malaria in combination with other antimalarial medications

Dosage

Children: Refer to BNF for Children for age-appropriate dosing recommendations.

Adults: Refer to BNF for specific dosing guidelines based on the severity of malaria and combination therapy used. Commonly used doses may vary.

Mechanism of action

Dihydroartemisinin acts by binding to haem within the Plasmodium falciparum parasite. It is believed to bind to haem produced during the parasite's haem biosynthesis pathway in the early ring stage, and later to haem released from haemoglobin digestion. This binding triggers a reductive scission of the endoperoxide bridge, leading to the generation of a reactive oxygen species. This species further leads to the formation of a reactive carbon radical, which alkylates multiple protein targets within the parasite, contributing to its antimalarial activity. Notably, it irreversibly inhibits the sarco/endoplasmic reticulum Ca2+ ATPase pump of Plasmodium falciparum.

Pharmacodynamics

Dihydroartemisinin forms a reactive carbon radical intermediate that is instrumental in killing Plasmodium falciparum through the alkylation of diverse proteins. This mechanism is thought to disrupt various cellular functions within the parasite, ultimately leading to its death.

Pharmacokinetics

Dihydroartemisinin is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. It is extensively metabolized in the liver, primarily through cytochrome P450 enzymes, leading to the formation of several metabolites. The elimination half-life is relatively short, ranging from 1 to 3 hours. The drug is primarily excreted in urine and bile, making it effective for short-term treatment but necessitating multiple doses for sustained efficacy.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Headache
• Fatigue
• Abdominal pain

Precautions

• Use with caution in patients with a history of hypersensitivity to artemisinin derivatives.
• Monitor for signs of malaria treatment failure, especially in cases of severe malaria.
• Assess liver function prior to and during treatment, as hepatic impairment can affect drug metabolism.

Pregnancy

Dihydroartemisinin is classified as category C. Animal studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Dihydroartemisinin is excreted in breast milk. Caution should be exercised when administering to nursing mothers. The effects on the infant are unknown.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable solution

Mechanism of action

Artemisinins, including Artenimol which is a major active metabolite of many artemisinins, are thought to act via a common mechanism. While the exact mechanism of action is not certain, theories exist as to how artemisinins produce their antimalarial effect. Artemisinins are believed to bind to haem within the *P. falciparum* parasite. The source of this haem varies with the life stage of the parasite. When the parasite is in the early ring stage artemisinins are believed to bind haem produced by the parasite's haem biosynthesis pathway. In later stages artemisinins likely bind to haem released by haemoglobin digestion. Once bound to haem, artemisinins are thought to undergo activation involving ferrous iron via reductive scission which splits the endoperoxide bridge to produce a reactive oxygen. This reactive oxygen is thought to undergo a subsequent intramolecular hydrogen abstraction to produce a reactive carbon radical. The carbon radical is believed to be the source of the drugs potent activity against *P. falciparum* by alkylating a wide array of protein targets. The nature and magnitude of the effect on specific protein function as a result of this alkylation is unknown. One target which has been the focus of research is the sarco/endoplasmic reticulum Ca2+ ATPase pump of *P. falciparum*. Artemisinins have been found to irreversably bind to and inhibit this protein at a binding site similar to that of Thapsigargin. The mechanism is likely the same as for other proteins, namely alkylation via the carbon radical intermediate. Artemisinins appear to preferentially collect in infected erythrocytes, concentrating the drug by several hundred-fold compared to uninfected cells. This may play a role in why little alkylation is seen in uninfected erythrocytes. A 2025 systematic review notes Dihydroartemisinine's pharmacological activities as being antimalarial and anticancer, and that it has shown promise in improving nonalcoholic steatohepatitis (NASH) by reducing  liver fat, inflammation, and fibrosis via Inhibition of  lipogenesis (SREBP-1c, FASN, SCD1) and promotion of  lipolysis (PGC1α, CPT-1a).

Pharmacodynamics

Artenimol is thought to form a reactive carbon radical intermediate which kills *P. falciparum* through alkylation of a wide array of proteins.